Your browser is no longer supported. Please, upgrade your browser.
Settings
CMRX Chimerix, Inc. daily Stock Chart
CMRX [NASD]
Chimerix, Inc.
Index- P/E- EPS (ttm)-1.65 Insider Own1.50% Shs Outstand46.76M Perf Week5.04%
Market Cap302.07M Forward P/E- EPS next Y-1.64 Insider Trans-12.53% Shs Float45.45M Perf Month20.30%
Income-76.40M PEG- EPS next Q-0.36 Inst Own77.40% Short Float5.54% Perf Quarter38.63%
Sales5.70M P/S52.99 EPS this Y38.30% Inst Trans-3.60% Short Ratio5.21 Perf Half Y12.35%
Book/sh5.95 P/B1.09 EPS next Y1.80% ROA-25.10% Target Price6.88 Perf Year32.92%
Cash/sh4.96 P/C1.30 EPS next 5Y- ROE-26.00% 52W Range3.50 - 6.64 Perf YTD40.43%
Dividend- P/FCF- EPS past 5Y41.20% ROI-28.20% 52W High-2.71% Beta1.57
Dividend %- Quick Ratio23.40 Sales past 5Y-14.00% Gross Margin- 52W Low84.57% ATR0.28
Employees87 Current Ratio23.40 Sales Q/Q-35.50% Oper. Margin- RSI (14)61.91 Volatility4.70% 4.60%
OptionableYes Debt/Eq0.00 EPS Q/Q60.70% Profit Margin- Rel Volume0.57 Prev Close6.49
ShortableYes LT Debt/Eq0.00 EarningsMar 02 BMO Payout- Avg Volume483.16K Price6.46
Recom3.00 SMA205.71% SMA5013.94% SMA20033.13% Volume274,978 Change-0.46%
Aug-09-16Reiterated FBR Capital Mkt Perform $9 → $8
Feb-23-16Reiterated FBR Capital Mkt Perform $14 → $10
Feb-23-16Downgrade Morgan Stanley Equal-Weight → Underweight
Feb-23-16Downgrade Barclays Overweight → Equal Weight $12 → $6
Feb-22-16Downgrade Citigroup Buy → Neutral
Dec-29-15Downgrade JP Morgan Overweight → Neutral $65 → $15
Dec-28-15Reiterated Piper Jaffray Overweight $63 → $10
Dec-28-15Downgrade FBR Capital Outperform → Mkt Perform $73 → $14
Dec-17-15Initiated UBS Buy $55
Oct-05-15Downgrade Morgan Stanley Overweight → Equal-Weight
Sep-03-15Initiated Citigroup Buy
Aug-18-15Initiated FBR Capital Outperform $73
Aug-06-15Reiterated Brean Capital Buy $50 → $57
May-11-15Reiterated Brean Capital Buy $45 → $50
Mar-04-15Initiated Barclays Overweight $55
Feb-12-15Reiterated Stifel Buy $47 → $57
Dec-31-14Reiterated Brean Capital Buy $33 → $45
Jul-08-14Resumed Brean Capital Buy $33
Jun-24-14Initiated Brean Capital Buy $33
Mar-20-17 12:02PM  Chimerix, Inc. :CMRX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
Mar-14-17 02:56PM  Chimerix, Inc. :CMRX-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
Mar-08-17 01:04PM  CHIMERIX INC Financials
Mar-02-17 05:16PM  Edited Transcript of CMRX earnings conference call or presentation 2-Mar-17 1:30pm GMT
08:01AM  CHIMERIX INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
07:29AM  Chimerix reports 4Q loss
07:07AM  Q4 2016 Chimerix Inc Earnings Release - Before Market Open
07:00AM  Chimerix Announces Fourth Quarter and Full Year 2016 Financial Results GlobeNewswire
Feb-28-17 08:00AM  Chimerix to Present at Cowen and Company 37th Annual Health Care Conference GlobeNewswire
Feb-27-17 08:30AM  Universal Health (UHS) Q4 Earnings: What's in the Cards?
Feb-23-17 08:00AM  Chimerix to Announce Fourth Quarter and Full Year 2016 Financial Results on March 2, 2017 GlobeNewswire
Feb-22-17 08:00AM  Chimerix Announces Final Data from AdVise Trial of Brincidofovir at BMT Tandem Meetings GlobeNewswire
Feb-10-17 08:49AM  5 Breakout Stocks for Superior Returns
Jan-24-17 07:11AM  Will Chimerix (CMRX) Continue to Surge Higher? -7.22%
Jan-13-17 08:51AM  Falling Earnings Estimates Signal Weakness Ahead for Agios Pharmaceuticals (AGIO)
Jan-06-17 08:02AM  CHIMERIX INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
08:00AM  Chimerix Announces Preliminary Data from Ongoing Phase 1 Dose Escalation Study of Intravenous Brincidofovir in Healthy Subjects GlobeNewswire
Jan-05-17 04:01PM  Chimerix Appoints Randall Lanier, PhD as Chief Science Officer, and Roy W. Ware, PhD, MBA as Chief Manufacturing and Technology Officer GlobeNewswire
Jan-04-17 08:00AM  Chimerix to Present at the 35th Annual J.P. Morgan Healthcare Conference GlobeNewswire +6.83%
Dec-09-16 01:06PM  Should You Buy Beigene Ltd (ADR) (BGNE)? at Insider Monkey
Dec-08-16 10:26AM  Here is What Hedge Funds Think About Chimerix Inc (CMRX) at Insider Monkey
Dec-05-16 11:57AM  ETFs with exposure to Chimerix, Inc. : December 5, 2016
Nov-17-16 08:00AM  Chimerix Presents Data from a Preclinical Study of Intravenous Brincidofovir at AAPS GlobeNewswire +10.02%
Nov-10-16 12:09PM  ETFs with exposure to Chimerix, Inc. : November 10, 2016
Nov-09-16 11:38AM  Chimerix, Inc. :CMRX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 9, 2016 +10.98%
08:00AM  Chimerix to Present at Upcoming Investor Conferences GlobeNewswire
Nov-07-16 01:14PM  Edited Transcript of CMRX earnings conference call or presentation 7-Nov-16 1:30pm GMT
07:54AM  CHIMERIX INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
07:36AM  Chimerix reports 3Q loss
07:07AM  Q3 2016 Chimerix Inc Earnings Release - Before Market Open
07:00AM  Chimerix Announces Third Quarter 2016 Financial Results GlobeNewswire
Oct-31-16 08:00AM  Chimerix to Announce Third Quarter 2016 Financial Results on November 7, 2016 GlobeNewswire
Oct-27-16 04:01PM  Chimerix Announces Presentation at IDWeek of Detailed 24-Week Results from AdVise Trial of Brincidofovir for the Treatment of Adenovirus Infection in Allogeneic Hematopoietic Cell Transplant Recipients GlobeNewswire
Oct-21-16 09:51AM  ETFs with exposure to Chimerix, Inc. : October 21, 2016
Sep-27-16 09:56AM  ETFs with exposure to Chimerix, Inc. : September 27, 2016
Sep-08-16 10:11AM  ETFs with exposure to Chimerix, Inc. : September 8, 2016
Sep-06-16 08:00AM  Chimerix to Present at the Morgan Stanley Global Healthcare Conference GlobeNewswire +6.28%
Sep-01-16 11:08AM  CEOs Are Buying and Selling Shares of These Companies at Insider Monkey
Aug-26-16 10:20AM  ETFs with exposure to Chimerix, Inc. : August 26, 2016
Aug-15-16 10:17AM  ETFs with exposure to Chimerix, Inc. : August 15, 2016
Aug-12-16 01:01PM  Chimerix, Inc. :CMRX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016
Aug-08-16 12:59PM  Edited Transcript of CMRX earnings conference call or presentation 8-Aug-16 12:30pm GMT
08:06AM  CHIMERIX INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
07:41AM  Chimerix reports 2Q loss
07:30AM  Chimerix Announces Second Quarter 2016 Financial Results GlobeNewswire
07:07AM  Q2 2016 Chimerix Inc Earnings Release - Before Market Open
Aug-01-16 08:00AM  Chimerix to Announce Second Quarter 2016 Financial Results on August 8, 2016 GlobeNewswire
Jul-18-16 01:35PM  ETFs with exposure to Chimerix, Inc. : July 18, 2016
Jun-29-16 07:15AM  7 Stocks Under $10 Making Big Moves +5.51%
Jun-28-16 06:03AM  CHIMERIX INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders +7.02%
Jun-20-16 02:14PM  ETFs with exposure to Chimerix, Inc. : June 20, 2016
Jun-07-16 08:00AM  Chimerix to Participate in Panel on North Carolinas Role in Biodefense Preparation at Medical, Biomedical and Biodefense Symposium GlobeNewswire
Jun-06-16 09:12AM  Premarket Research Report Covering the Biotech Industry
May-19-16 07:10PM  ETFs with exposure to Chimerix, Inc. : May 19, 2016
May-16-16 10:55AM  Chimerix, Inc. :CMRX-US: Earnings Analysis: Q1, 2016 By the Numbers
May-09-16 04:17PM  Durham drug developer Chimerix shares rise, fall on trial results at bizjournals.com
12:22PM  Edited Transcript of CMRX earnings conference call or presentation 9-May-16 12:30pm GMT
08:12AM  CHIMERIX INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
07:53AM  Chimerix reports 1Q loss
07:30AM  Chimerix Announces Top-Line Interim AdVise Data and First Quarter 2016 Financial Results GlobeNewswire
07:07AM  Q1 2016 Chimerix Inc Earnings Release - Before Market Open
May-06-16 10:04AM  Here's Why Chimerix Inc Jumped 14.3% in April at Motley Fool
May-03-16 06:00PM  Chimerix to Announce First Quarter 2016 Financial Results on May 9, 2016 GlobeNewswire
Apr-28-16 01:08PM  ETFs with exposure to Chimerix, Inc. : April 28, 2016 at Capital Cube
Apr-26-16 03:00PM  Research Triangle area's biotech sector in steep bear market at American City Business Journals
Apr-18-16 09:05AM  Time For Another Biotech Rally Accesswire +6.78%
Apr-15-16 03:10PM  The best-run public companies in the Research Triangle area at bizjournals.com
Apr-13-16 07:13PM  ETFs with exposure to Chimerix, Inc. : April 13, 2016
Mar-30-16 01:59PM  Americans Don't Really Understand The Zika Virus
Mar-22-16 09:00AM  Are These Biotech Stocks Worth your Attention? CELG, ARIA, EXEL, and CMRX Accesswire
Mar-21-16 09:00AM  Biotechs in the News Accesswire
Mar-18-16 08:57AM  These 7 Stocks Under $10 Are Set to Soar Higher at TheStreet
Mar-09-16 08:30AM  Chimerix to Present at the Barclays Global Healthcare Conference GlobeNewswire
Mar-07-16 01:22PM  A Potential Answer To Antibiotic Resistance Accesswire +5.42%
12:19PM  Chimerix, Inc. :CMRX-US: Earnings Analysis: Q4, 2015 By the Numbers
Mar-02-16 06:57AM  7 Stocks Under $10 Making Big Breakout Moves at TheStreet
Mar-01-16 08:30AM  Chimerix, Inc., (NASDAQ: CMRX) Market Cap Has Fallen Below the Book Value of Equity Accesswire +7.38%
08:00AM  Chimerix to Present at Cowen and Company 36th Annual Health Care Conference GlobeNewswire
Feb-29-16 04:45PM  Chimerix cuts workforce by 20 percent after 'unexpected' trial results at bizjournals.com
03:33PM  Chimerix (CMRX) Stock Down Following Q4 Results at TheStreet
12:08PM  Edited Transcript of CMRX earnings conference call or presentation 29-Feb-16 1:30pm GMT
08:55AM  Chimerix Rises Slightly on Revenue Beat
08:13AM  CHIMERIX INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
07:47AM  Chimerix reports 4Q loss
07:30AM  Chimerix Announces Fourth Quarter and Full Year 2015 Financial Results GlobeNewswire
07:07AM  Q4 2015 Chimerix Inc Earnings Release - Before Market Open
Feb-28-16 10:05AM  6 Companies That Destroyed Shareholders Last Week at 24/7 Wall St.
Feb-24-16 09:45AM  These Cheap Stocks Could Be Headed Higher. Here's Why! Accesswire +12.78%
Feb-23-16 04:04PM  The 52-Week Low Club for Tuesday at 24/7 Wall St.
02:55PM  With depressed share value, is Chimerix a takeover candidate? at bizjournals.com
11:20AM  Chimerix CEO Michelle Berrey charts course after trials for its signature drug is halted at bizjournals.com
10:40AM  Chimerix downgraded by Morgan Stanley and Barclays
08:07AM  Barclays Downgrades Chimerix Following Lowered Expectations
Feb-22-16 05:15PM  Chimerix charts course after halting Phase 3 trials at bizjournals.com -40.37%
04:05PM  Chimerix to Announce Fourth Quarter and Full Year 2015 Financial Results on February 29, 2016 GlobeNewswire
04:04PM  The 52-Week Low Club for Monday at 24/7 Wall St.
03:53PM  Chimerix: When Good Is Bad In Biotech at Forbes
03:15PM  Stocks rally as commodities lead the way; Uber's latest scandal
01:38PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud by Chimerix, Inc. and Certain Officers and Directors -- CMRX PR Newswire
01:10PM  Trending Tickers: LL, FCX, BAC, FB
Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of serious viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of serious adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients. It is also developing CMX521, a nucleoside analog that is in preclinical stage for the treatment and prevention of norovirus; and CMX157, a nucleoside analog, which is in Phase II clinical stage to treat HIV and hepatitis B virus infection. It has a license agreement with ContraVir Pharmaceuticals for the development and commercialization of brincidofovir and CMX157 for certain antiviral indications; and BARDA for the development of brincidofovir for the treatment of smallpox. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MARIO ERNESTDirectorDec 28Sale4.5424,291110,317268,535Dec 29 04:03 PM
MARIO ERNESTDirectorDec 27Sale4.6875,709354,050292,826Dec 29 04:03 PM
Berrey M MichellePresident and CEONov 29Option Exercise4.262,40010,224288,161Dec 01 04:17 PM
LEONARD JOHN M.DirectorSep 15Sale5.035,00025,1630Sep 16 06:46 PM
Berrey M MichellePresident and CEOAug 29Buy4.4722,417100,226281,238Aug 31 03:01 PM
MARIO ERNESTDirectorJun 24Buy3.7050,000184,845381,440Jun 28 03:17 PM
Berrey M MichellePresident and CEOJun 24Buy3.6913,18848,624258,821Jun 28 03:16 PM
MARIO ERNESTDirectorMay 13Buy4.5310,00045,328331,440May 16 01:56 PM
MARIO ERNESTDirectorMay 11Buy4.8524,200117,365321,440May 11 05:15 PM
MARIO ERNESTDirectorMay 10Buy4.768003,804297,240May 11 05:15 PM
MARIO ERNESTDirectorMay 04Option Exercise5.051,7618,893296,440May 05 05:05 PM
MARIO ERNESTDirectorApr 04Option Exercise5.051,7608,888294,679Apr 05 05:56 PM